(Total Views: 502)
Posted On: 11/02/2020 10:40:23 AM
Post# of 148908
“The SP jumped to the $2-3 range on the news Vyera HIV partnership news. nothing to do with covid.”
This is 100% inaccurate. The SP rose from .30 to around the $1.50 range following the Vyera deal, additionally cancer data, and early COVID talk. Not until March 30th did the SP break the $1.50 mark and spike to the $3.50 range. This spike immediately followed the injection of more S/C patients and NP being on Fox News discussing leronlimab as a COVID treatment. The spike above $1.50 was not correlated to HIV.
Additionally, the HIV combo BLA wasn’t filed until April 27th and the SP closed that day .56 higher than the previous. The RTF for the combo BLA was announced on July 13th and the SP closed at $3.70, down $1.03 from the previous trading day’s close of $4.73.
The run to $10 is a deeply debated topic. Dr. BP’s Ted Tlak was released around that time and there was hype surrounding potential interim data from the M2M and S/C trial. The combination of the two and the fact that COVId stocks were being heavily hyped, resulted in the run to $10. Many other COVID stocks made similar runs and similar pullbacks.
This is 100% inaccurate. The SP rose from .30 to around the $1.50 range following the Vyera deal, additionally cancer data, and early COVID talk. Not until March 30th did the SP break the $1.50 mark and spike to the $3.50 range. This spike immediately followed the injection of more S/C patients and NP being on Fox News discussing leronlimab as a COVID treatment. The spike above $1.50 was not correlated to HIV.
Additionally, the HIV combo BLA wasn’t filed until April 27th and the SP closed that day .56 higher than the previous. The RTF for the combo BLA was announced on July 13th and the SP closed at $3.70, down $1.03 from the previous trading day’s close of $4.73.
The run to $10 is a deeply debated topic. Dr. BP’s Ted Tlak was released around that time and there was hype surrounding potential interim data from the M2M and S/C trial. The combination of the two and the fact that COVId stocks were being heavily hyped, resulted in the run to $10. Many other COVID stocks made similar runs and similar pullbacks.
(4)
(0)Scroll down for more posts ▼
